This inventor holds 3 USPTO granted patents. Top assignee: Promore Pharma Ab. Active years: 2019-2021.
Company Filing History:
Years Active: 2019-2021
Title: Alvar Grönberg: Innovator in Pharmaceutical Formulations
Introduction
Alvar Grönberg is a notable inventor based in Solna, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of chronic ulcers. With a total of 3 patents to his name, Grönberg's work is paving the way for advancements in wound care.
Latest Patents
Grönberg's latest patent focuses on a pharmaceutical formulation that includes LL-37 or a pharmaceutically-acceptable salt thereof. This formulation is designed for the treatment of chronic ulcer wounds, such as hard-to-heal venous leg ulcers or diabetic foot ulcers. The method involves the topical application of the formulation to the ulcer, followed by the application of a dressing. The application ensures that the dose of LL-37 at the wound site is below about 80 µg of LL-37 per cm² of wound area, and/or below about 26.7 µg of LL-37 per cm² of wound area per day of treatment.
Career Highlights
Grönberg is currently associated with Promore Pharma AB, where he continues to innovate in the pharmaceutical sector. His work is instrumental in developing effective treatments for chronic wounds, which can significantly improve patient outcomes.
Collaborations
Grönberg collaborates with esteemed colleagues such as Christine Dieterich and Margit Mahlapuu. Their combined expertise enhances the research and development efforts at Promore Pharma AB.
Conclusion
Alvar Grönberg's contributions to pharmaceutical formulations demonstrate his commitment to improving healthcare solutions. His innovative approach to treating chronic ulcers is a testament to his skills as an inventor.